Skip to main content

Table 3 Discrepancies between visual and quantitative assessments (above/below cut-off values for receptor positivity) for [18F]FES (A) and [18F]FDHT PET (B)

From: Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study

A [18F]FES

Observer 1

 

Observer 2

 
 

Visible (n= 64)

Not visible (n= 36)

Visible (n= 69)

Not visible (n= 38)

SUVmax ≥ 1.5

62 (97%)

16 (44%)

68 (99%)

15 (39%)

SUVmax < 1.5

2 (3%)

20 (56%)

1 (1%)

23 (61%)

SUVpeak ≥ 1.2

54 (84%)

19 (53%)

67 (97%)

16 (42%)

SUVpeak < 1.2

10 (16%)

17 (47%)

2 (3%)

22 (58%)

SUVmean ≥ 1.1

57 (89%)

8 (22%)

67 (97%)

11 (29%)

SUVmean < 1.1

7 (11%)

28 (78%)

2 (3%)

27 (71%)

B [18F]FDHT

Observer 1

 

Observer 2

 
 

Visible (n= 36)

Not visible (n= 62)

Visible (n= 37)

Not visible (n= 56)

SUVmax ≥ 1.9

31 (86%)

19 (31%)

32 (86%)

29 (52%)

SUVmax < 1.9

5 (14%)

43 (69%)

5 (14%)

27 (48%)

SUVpeak ≥ 1.6

30 (83%)

25 (40%)

33 (89%)

30 (54%)

SUVpeak < 1.6

6 (17%)

37 (60%)

4 (11%)

26 (46%)

SUVmean ≥ 1.3

31 (86%)

20 (32%)

33 (89%)

30 (54%)

SUVmean < 1.3

5 (14%)

42 (68%)

4 (11%)

26 (46%)

  1. Not evaluable lesions were excluded as reported in Table 2